Monitoring Enables Progress: A Nationwide Quality Improvement Program in Children With Crohn's Disease.

OBJECTIVES In this quality improvement program, named QPID, we constructed a nation-wide platform that prospectively recorded clinically important quality indicators in pediatric inflammatory bowel diseases (PIBD), aiming at improving clinical management across the country. METHODS Representatives of all 21 PIBD facilities in Israel formed a Delphi group to select quality indicators (process and outcomes), recorded prospectively over 2 years in children with Crohn's disease 2-18 years of age seen in the outpatient clinics. Monthly anonymized reports were distributed to all centers, allowing comparison and improvement. Trends were analyzed using the Mann-Kendall test, reporting τ(tau) values. RESULTS The indicators of 3,254 visits from 1,709 patients were recorded from 09/2017 to 09/2019 (mean age 14.7 ± 3.1 years, median disease duration 1.8 years (IQR 0.69-4.02)). An increase in three of five process indicators was demonstrated: obtaining drug levels of anti-TNF (tumor necrosis factor) (τ = 0.4; p = 0.005), utilization of fecal calprotectin (τ = 0.38; p = 0.008) and bone density testing (τ = 0.45; p = 0.002). Among outcome indicators, three of nine improved as measured during the preceding year: calprotectin < 300 μg/mg (τ = 0.35; p = 0.015), and "resolution of inflammation" defined as a composite of endoscopy, imaging and fecal calprotectin (τ = 0.39 p = 0.007). Endoscopic healing reached borderline significance (τ = 0.28, p = 0.055). An increase in the use of biologics throughout the study was observed (τ = 0.47; p = 0.001) with a concurrent decrease in the use of immunomodulators (τ = -0.47 p = 0.001). CONCLUSIONS Quality improvement nationwide programs can be implemented with limited resources while facilitating a standardization of care, and may be associated with improvements in measured indicators.